Novo Nordisk to Acquire Ocedurenone for Uncontrolled Hypertension
1 Mins read
Novo Nordisk A/S (NVO) is set to acquire Ocedurenone, a promising pill with potential applications in cardiovascular and kidney disease, from KBP…
DaVita Responds to Trial Results of Novo Nordisk's Ozempic Treatment
1 Mins read
Dialysis company DaVita Inc. has issued a statement in response to the recent news from Novo Nordisk regarding its Ozempic treatment for…